Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Salbutamol (Albuterol)

AEMPS

Short-acting beta-2 adrenergic agonists (SABA)

ATC code: R03AC02

Brand names: Ventolin, ProAir

Updated · Methodology

Indications

A

Acute bronchospasm

First line

First-line reliever for acute bronchospasm of any cause (asthma, COPD, allergic airway edema, exercise). Dose via pMDI: 2 puffs of 100 mcg (total 200 mcg), repeatable in 20 minutes. Via nebulizer in severe exacerbation: 2.5–5 mg in 2.5 mL saline, repeat every 20 minutes for up to 3 doses. Onset 5–15 minutes.

Used in children from the first year of life on clinical grounds. Always via spacer, with a face mask for the youngest.

Sources

  1. Cochrane Database Syst Rev: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. (2013)
  2. Cochrane Database Syst Rev: Continuous versus intermittent beta-agonists in the treatment of acute asthma. (2003)
  3. GINA: Global Strategy for Asthma Management and Prevention (GINA 2026 report) (2026)
  4. GOLD: Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD 2026 report) (2026)

ICD-10: J98.0 · ICD-11: CA23.2

A

Chronic obstructive pulmonary disease

First line

2024 recommends salbutamol as a rescue bronchodilator in COPD. Maintenance therapy relies on long-acting bronchodilators (LAMA and/or LABA), while SABA is used on demand for episodes of dyspnea.

Sources

  1. J Hosp Med: Clinical guideline highlights for the hospitalist: GOLD COPD update 2024. (2024)
  2. Thorax: Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. (2003)

ICD-10: J44 · ICD-11: CA22

A

Exercise-induced bronchoconstriction

First line

Per ATS 2013 and 2024, salbutamol 200 mcg taken 15 minutes before exercise is first-line prophylaxis for exercise-induced bronchoconstriction in patients without underlying asthma. In asthma patients, daily prophylactic SABA is not needed – optimize controller ICS therapy. Frequent pre-exercise SABA use leads to tachyphylaxis.

Sources

  1. Am J Respir Crit Care Med: An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. (2013)
  2. Cochrane Database of Systematic Reviews: Beta2-agonists for exercise-induced asthma (2013)
  3. GINA — Global Strategy for Asthma Management and Prevention (2024): GINA — Global Strategy for Asthma Management and Prevention (2024) (2024)

ICD-10: J45.9 · ICD-11: CA23.21

B

Asthma

Individual decision

Per 2024, the preferred reliever in adults and adolescents from age 12 across all asthma steps is a fixed combination of low-dose ICS + formoterol (e.g., budesonide/formoterol) rather than salbutamol. SABA monotherapy is associated with increased asthma mortality (Cochrane meta-analysis). SABA use more than twice weekly is a marker of poor control. In children under 5, salbutamol remains the first-line reliever, with ICS added as a controller.

As a reliever only. SABA monotherapy is contraindicated in persistent asthma.

Sources

  1. GINA: Global Strategy for Asthma Management and Prevention (2024)
  2. New England Journal of Medicine: Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma (2018)
  3. New England Journal of Medicine: As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma (2018)

ICD-10: J45 · ICD-11: CA23

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Muscle mass gain (bodybuilding self-use)

Not recommended

Bodybuilders take Salbutamol expecting an anabolic beta-2 agonist effect. Controlled human trials do find a weak, sex-dependent anabolic signal: some studies report increased myofibrillar protein synthesis and small lean-mass gain. The effect splits by sex. Women show body recomposition, men show no lean-mass gain, and in neither case does it amount to clinically meaningful muscle gain for bodybuilding. Salbutamol also lowers VO2max and reduces quadriceps strength in women. Its acute effect is limited to anaerobic power, with no gain in maximal strength. No international guideline recommends Salbutamol for muscle gain in healthy people. WADA bans oral Salbutamol, and high doses carry a risk of arrhythmia and sudden death.

Sources

  1. J Physiol: Beta(2) -adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. (2018)
  2. Scand J Med Sci Sports: Effects of acute and 2-week administration of oral salbutamol on exercise performance and muscle strength in athletes. (2016)
  3. ERJ Open Res: Inhaled salbutamol induces leanness in well-trained healthy females but not males during a period of endurance training: a randomised controlled trial. (2023)
  4. J Physiol: Muscle hypertrophic effect of inhaled beta(2) -agonist is associated with augmented insulin-stimulated whole-body glucose disposal in young men. (2022)
  5. Scand J Med Sci Sports: Effect of beta(2) -adrenergic agonist and resistance training on maximal oxygen uptake and muscle oxidative enzymes in men. (2019)
F

Weight loss

Not recommended

In fitness communities salbutamol is sometimes used as a 'clenbuterol replacement' for thermogenic effects and weight loss. This use is dangerous: tachycardia, tremor, hypokalaemia, and arrhythmias at systemic doses, especially combined with other beta-agonists. International obesity guidelines (, ) do not mention salbutamol. Inhaled delivery has minimal systemic bioavailability, so 'weight loss' use requires oral administration or high doses – doubling the risk.

Sources

  1. Am J Physiol Endocrinol Metab: Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. (2003)
  2. J Clin Endocrinol Metab: beta(1)- and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. (2001)
  3. Horm Metab Res: Effects of salbutamol and butoxamine on the human fat cell adenylate cyclase. (1980)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Selective beta-2 adrenergic agonist on bronchial smooth muscle. Relaxes smooth muscle and dilates bronchi via adenylyl cyclase activation and increased cAMP. Onset 5–15 minutes after inhalation, duration 4–6 hours. A reliever, not a controller. Since 2019, SABA monotherapy in asthma is no longer recommended — it is associated with worse control and increased mortality.

Safety

Contraindications

  • Hypersensitivity
  • Uncorrected severe tachyarrhythmias

Serious adverse effects

  • Paradoxical bronchospasm (rare, requires immediate discontinuation)
  • Severe ventricular arrhythmias (rare, in overdose)
  • Lactic acidosis with high nebulized doses in severe asthma

Common adverse effects

  • Hand tremor
  • Tachycardia, palpitations
  • Headache
  • Hypokalemia (with high nebulized doses)
  • Throat irritation, cough after inhalation

Pregnancy: can you take Salbutamol (Albuterol)?

AEMPS summary of product characteristics (section 4.6): animal studies have shown reproductive toxicity. Salbutamol should be considered in pregnancy only if the expected benefit to the mother is greater than any possible risk to the fetus. During extensive worldwide marketing experience, isolated cases of various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of treated patients, some of whom were taking several medicines. Since no consistent pattern of defects can be identified and the background rate of congenital anomalies in pregnant women is 2–3%, no link with salbutamol can be established.

Breastfeeding: can you take Salbutamol (Albuterol)?

Hale L1 · Compatible

Compatible with breastfeeding. Systemic bioavailability after inhalation is low, with minimal transfer to milk.

Maternal half-life
4 h
Maternal peak time
2.5 h
Calculate RIDSafe feeding windowFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Use as needed for wheeze, cough, or breathlessness. Two pMDI puffs 30 seconds apart. If insufficient, repeat in 20 minutes. With no relief after 6–8 actuations or with need above 4 times daily, seek urgent medical care — this signals a severe exacerbation.

Device compatibility

Via pMDI in children under 5, elderly, and severe exacerbations, use a spacer with face mask — lower-airway delivery increases 2–4 fold. Via nebulizer in severe exacerbations, use a jet (compressor) nebulizer with 2.5–5 mg in 2.5 mL saline. Ultrasonic and mesh nebulizers also work for salbutamol solutions, but jet nebulizers are the hospital standard.

Common myths

Myth: 'salbutamol can be inhaled daily for prevention'. Fact: daily SABA without ICS in asthma raises mortality. Controllers (ICS or ICS + formoterol) are the foundation; SABA is for symptoms only.

Myth: 'salbutamol is addictive'. Fact: there is no physiological dependence. High-frequency use signals poor control of the underlying disease — controller therapy needs optimization.

Myth: 'salbutamol is a doping agent in sport'. Fact: WADA permits inhaled doses up to 1600 mcg daily with a medical indication. Oral and injectable use is prohibited without a TUE.
Label mentions3 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • Moderatediuréticosclass named in the label
    «El tratamiento con agonistas ? 2 puede producir una hipocalemia potencialmente grave, principalmente tras la administración de presentaciones parenterales y nebulizadas. Se recomienda una precaución…»

    AEMPS, section 4.4 · Open on CIMA

  • IMAOclass named in the label
    «Salbutamol no está contraindicado en pacientes bajo tratamiento con inhibidores de la monoaminooxidasa (IMAO).»

    AEMPS, section 4.5 · Open on CIMA

  • Propranolol
    «Salbutamol y los fármacos ? -bloqueantes no selectivos, como propranolol, normalmente no deben ser prescritos conjuntamente.»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Salbutamol (Albuterol) used for?

Salbutamol (Albuterol) is evaluated for the following indications with varying evidence strength: Chronic obstructive pulmonary disease (evidence tier A), Exercise-induced bronchoconstriction (evidence tier A), Acute bronchospasm (evidence tier A). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Salbutamol (Albuterol)?

Common side effects of Salbutamol (Albuterol) (≥ 1 in 100): Hand tremor, Tachycardia, palpitations, Headache, Hypokalemia (with high nebulized doses), Throat irritation, cough after inhalation. See the Safety section for uncommon and serious reactions.

Is Salbutamol (Albuterol) safe during pregnancy?

AEMPS summary of product characteristics (section 4.6): animal studies have shown reproductive toxicity. Salbutamol should be considered in pregnancy only if the expected benefit to the mother is greater than any possible risk to the fetus. During extensive worldwide marketing experience, isolated cases of various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of treated patients, some of whom were taking several medicines. Since no consistent pattern of defects can be identified and the background rate of congenital anomalies in pregnant women is 2–3%, no link with salbutamol can be established.

Is Salbutamol (Albuterol) compatible with breastfeeding?

Compatible with breastfeeding. Systemic bioavailability after inhalation is low, with minimal transfer to milk.

Who should not take Salbutamol (Albuterol)?

Salbutamol (Albuterol) is contraindicated in: Hypersensitivity; Uncorrected severe tachyarrhythmias. Full list in the Safety section.

salbutamol can be inhaled daily for prevention

daily SABA without ICS in asthma raises mortality. Controllers (ICS or ICS + formoterol) are the foundation; SABA is for symptoms only.

salbutamol is addictive

there is no physiological dependence. High-frequency use signals poor control of the underlying disease — controller therapy needs optimization.

salbutamol is a doping agent in sport

WADA permits inhaled doses up to 1600 mcg daily with a medical indication. Oral and injectable use is prohibited without a TUE.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Salmeterol, Salmeterol + Fluticasone, Theophylline, Tiotropium, Beclomethasone dipropionate, Fluticasone, Ipratropium bromide, Aclidinium